[go: up one dir, main page]

MEP22608A - Cyclic urea derivatives, preparation method thereof and pharmaceutical use of same as kinase inhibitors - Google Patents

Cyclic urea derivatives, preparation method thereof and pharmaceutical use of same as kinase inhibitors

Info

Publication number
MEP22608A
MEP22608A MEP-226/08A MEP22608A MEP22608A ME P22608 A MEP22608 A ME P22608A ME P22608 A MEP22608 A ME P22608A ME P22608 A MEP22608 A ME P22608A
Authority
ME
Montenegro
Prior art keywords
nr5r6
cycloalkyl
alkyl
optionally substituted
alkenyl
Prior art date
Application number
MEP-226/08A
Other languages
Bosnian (bs)
English (en)
Inventor
Marcel Patek
Anil Nair
Augustin Hittinger
Conception Nemecek
Daniel Bond
Greg Harlow
Herve Bouchard
Jacques Mauger
Jean-Luc Malleron
Mark Palermo
Fahad Al-Obeidi
Thomas Faitg
Hartmut Strobel
Sven Ruf
Kurt Ritter
Youssef El-Ahmad
Dominique Lesuisse
Didier Benard
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Publication of MEP22608A publication Critical patent/MEP22608A/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
MEP-226/08A 2003-01-31 2004-01-28 Cyclic urea derivatives, preparation method thereof and pharmaceutical use of same as kinase inhibitors MEP22608A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0301098A FR2850652B1 (fr) 2003-01-31 2003-01-31 Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
PCT/FR2004/000188 WO2004070050A2 (fr) 2003-01-31 2004-01-28 Derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases

Publications (1)

Publication Number Publication Date
MEP22608A true MEP22608A (en) 2010-06-10

Family

ID=32696243

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-226/08A MEP22608A (en) 2003-01-31 2004-01-28 Cyclic urea derivatives, preparation method thereof and pharmaceutical use of same as kinase inhibitors

Country Status (24)

Country Link
EP (1) EP1599464B1 (xx)
JP (1) JP4604020B2 (xx)
KR (1) KR20050098286A (xx)
CN (1) CN1768054A (xx)
AR (1) AR042936A1 (xx)
AT (1) ATE482207T1 (xx)
AU (1) AU2004209319A1 (xx)
BR (1) BRPI0407091A (xx)
CA (1) CA2513631A1 (xx)
DE (1) DE602004029236D1 (xx)
FR (1) FR2850652B1 (xx)
HR (1) HRP20050679A2 (xx)
MA (1) MA27651A1 (xx)
ME (1) MEP22608A (xx)
MX (1) MXPA05007407A (xx)
NO (1) NO20054006L (xx)
NZ (1) NZ541270A (xx)
PE (1) PE20040808A1 (xx)
PL (1) PL377811A1 (xx)
RS (1) RS20050657A (xx)
RU (1) RU2341523C2 (xx)
TW (1) TW200505898A (xx)
WO (1) WO2004070050A2 (xx)
ZA (1) ZA200505934B (xx)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE027546T2 (en) * 2003-08-29 2016-10-28 Brigham & Womens Hospital Inc Hydantoin derivatives as cell necrosis inhibitors
US7700603B2 (en) 2003-12-15 2010-04-20 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7763609B2 (en) 2003-12-15 2010-07-27 Schering Corporation Heterocyclic aspartyl protease inhibitors
US7592348B2 (en) 2003-12-15 2009-09-22 Schering Corporation Heterocyclic aspartyl protease inhibitors
AU2004305075A1 (en) 2003-12-19 2005-07-07 The Regents Of The University Of California Methods and materials for assessing prostate cancer therapies
NZ550102A (en) 2004-02-24 2010-10-29 Univ California Methods and materials for assessing prostate cancer therapies and compounds (thiohydantoine derivatives)
EP1621536A1 (en) * 2004-07-27 2006-02-01 Aventis Pharma S.A. Amino cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
EP1621535A1 (en) * 2004-07-27 2006-02-01 Aventis Pharma S.A. Substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
AU2007245022A1 (en) 2006-03-29 2007-11-08 The Regents Of The University Of California Diarylthiohydantoin compounds
AU2006248109B2 (en) 2005-05-13 2012-11-15 The Regents Of The University Of California Diarylhydantoin compounds
US7709516B2 (en) * 2005-06-17 2010-05-04 Endorecherche, Inc. Helix 12 directed non-steroidal antiandrogens
FR2896503B1 (fr) * 2006-01-23 2012-07-13 Aventis Pharma Sa Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
FR2896504B1 (fr) 2006-01-23 2012-07-13 Aventis Pharma Sa Nouveaux derives d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases
DK3100727T3 (en) 2006-03-27 2018-11-12 Univ California Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
JP2010500300A (ja) 2006-08-08 2010-01-07 サノフィ−アベンティス アリールアミノアリール−アルキル−置換イミダゾリジン−2,4−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用
JP2010512389A (ja) 2006-12-12 2010-04-22 シェーリング コーポレイション アスパルチルプロテアーゼ阻害剤
WO2009055053A2 (en) 2007-10-26 2009-04-30 The Regents Of The University Of California Diarylhydantoin compounds as androgen receptor modulators
US20120122889A1 (en) 2008-12-23 2012-05-17 President And Fellows Of Harvard College Small molecule inhibitors of necroptosis
EP3124481B1 (en) 2010-02-16 2018-03-28 Aragon Pharmaceuticals, Inc. Androgen receptor modulators and uses thereof
US8685256B2 (en) * 2010-12-21 2014-04-01 Cytec Technology Corp. Microdispersions of hydroxamated polymers and methods of making and using them
US8492556B2 (en) * 2011-11-10 2013-07-23 Allergan, Inc. 2,5-Dioxoimidazolidin-1-yl-3-phenylurea derivatives as formyl peptide receptor like-1 (FPRL-1) receptor modulators
SG10201912719TA (en) 2012-09-26 2020-02-27 Aragon Pharmaceuticals Inc Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
JOP20200097A1 (ar) 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
EP2968276A4 (en) 2013-03-15 2017-02-15 President and Fellows of Harvard College Hybrid necroptosis inhibitors
GB201312492D0 (en) * 2013-07-12 2013-08-28 Syngenta Ltd Herbicidal compounds
US10202373B2 (en) 2014-01-14 2019-02-12 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
KR20160122736A (ko) 2014-01-14 2016-10-24 밀레니엄 파머슈티컬스 인코퍼레이티드 헤테로아릴 및 이의 용도
CN107530350A (zh) 2014-12-11 2018-01-02 哈佛理事会 细胞坏死抑制剂及相关方法
TWI726969B (zh) 2016-01-11 2021-05-11 比利時商健生藥品公司 用作雄性激素受體拮抗劑之經取代之硫尿囊素衍生物
CN107619388A (zh) * 2016-07-13 2018-01-23 南京天印健华医药科技有限公司 作为fgfr抑制剂的杂环化合物
HRP20241015T1 (hr) * 2016-07-20 2024-11-08 Novartis Ag Derivati aminopiridina i njihova uporaba kao selektivnih alk-2 inhibitora
JP7201694B2 (ja) 2017-10-16 2023-01-10 アラゴン ファーマシューティカルズ,インコーポレイテッド 非転移性去勢抵抗性前立腺癌の治療のための抗アンドロゲン剤
WO2019088677A1 (ko) * 2017-10-31 2019-05-09 광주과학기술원 급성 골수성 백혈병 또는 전이성 유방암의 예방 또는 치료용 약제학적 조성물
TW202517640A (zh) * 2023-07-18 2025-05-01 愛爾蘭商赫瑞森治療學愛爾蘭指定活動公司 用於治療疾病之igf-1r的雜環抑制劑

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2329276A1 (fr) * 1975-10-29 1977-05-27 Roussel Uclaf Nouvelles imidazolidines substituees, procede de preparation, application comme medicament et compositions les renfermant
DE4228717A1 (de) * 1992-08-28 1994-03-03 Cassella Ag Imidazolidin-Derivate
DE19540027A1 (de) * 1995-10-27 1997-04-30 Gruenenthal Gmbh Substituierte Imidazolidin-2,4-dion-Verbindungen als pharmazeutische Wirkstoffe
TR199902124T2 (xx) * 1997-03-03 2000-06-21 Boehringer Ingelheim Pharmaceuticals, Inc. �ltihapl� hastal�klar�n tedavisinde yararl� k���k molek�ller.
DE19732928C2 (de) * 1997-07-31 2000-05-18 Gruenenthal Gmbh Verwendung substituierter Imidazolidin-2,4-dion-Verbindungen als Schmerzmittel
FR2796945B1 (fr) * 1999-07-30 2002-06-28 Sod Conseils Rech Applic Nouveaux derives d'hydantoines, de thiohydantoines, de pyrimidinediones et de thioxopyrimidinones, leurs procedes de preparation et leur application a titre de medicaments
JP3924531B2 (ja) * 2000-05-31 2007-06-06 田辺製薬株式会社 αLβ2介在細胞接着阻害剤
AU2003242249A1 (en) * 2002-05-16 2003-12-02 Bayer Cropscience Gmbh Pyridine carboxamide derivatives and their use as pesticides

Also Published As

Publication number Publication date
NO20054006D0 (no) 2005-08-29
RU2005127335A (ru) 2006-09-10
TW200505898A (en) 2005-02-16
BRPI0407091A (pt) 2006-01-24
JP2006517569A (ja) 2006-07-27
ZA200505934B (en) 2007-06-27
RS20050657A (sr) 2007-06-04
EP1599464A2 (fr) 2005-11-30
MA27651A1 (fr) 2005-12-01
MXPA05007407A (es) 2005-09-12
RU2341523C2 (ru) 2008-12-20
NO20054006L (no) 2005-10-13
CA2513631A1 (fr) 2004-08-19
HRP20050679A2 (en) 2006-12-31
CN1768054A (zh) 2006-05-03
PL377811A1 (pl) 2006-02-20
ATE482207T1 (de) 2010-10-15
PE20040808A1 (es) 2004-12-31
DE602004029236D1 (de) 2010-11-04
WO2004070050A2 (fr) 2004-08-19
KR20050098286A (ko) 2005-10-11
FR2850652A1 (fr) 2004-08-06
NZ541270A (en) 2008-11-28
AR042936A1 (es) 2005-07-06
JP4604020B2 (ja) 2010-12-22
FR2850652B1 (fr) 2008-05-30
AU2004209319A1 (en) 2004-08-19
EP1599464B1 (fr) 2010-09-22
WO2004070050A3 (fr) 2005-02-17

Similar Documents

Publication Publication Date Title
MEP22608A (en) Cyclic urea derivatives, preparation method thereof and pharmaceutical use of same as kinase inhibitors
TW200617004A (en) Novel heterocycle-substituted cyclic urea derivatives, preparation thereof and pharmaceutical use thereof as kinase inhibitors
NO20082976L (no) Svovelholdige cykliske ureaderivater, fremstilling derav og farmasoytisk anvendelse derav som kinaseinhibitorer
NO20052993L (no) 4,5-diaryltiazolderivater som CB-1 ligander.
MXPA03010129A (es) N-aroilaminas-ciclicas.
MXPA03008754A (es) Derivados de piridina fundidos para utilizarse como agonistas receptores vaniloide para tratar dolor.
HRP20080113T3 (hr) Supstituirani piridinilni i pirimidinilni derivati kao modulatori metabolizma i liječenje bolesti koje su s tim povezane
NO20063780L (no) Fremgangsmate for fremstilling av 2-aminitiazol-5-aromatisk karboksamid som kinase inhibitorer.
HUP0500339A2 (hu) GSK3-mal kapcsolatos állapotok kezelésére használható aril-aminok, eljárás előállításukra, az ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
NO20080456L (no) Nye 2,4-dianilinopyrimidinderivater, fremstilling derav og deres anvendelse som medikamenter, farmasoytiske sammensetninger og, spesielt, som IKK inhibitorer
NO20054329L (no) Adamantanderivater, fremgangsmater for deres fremstilling og farmasoytiske sammensetninger som innbefatter slike
NO20061406L (no) Organiske forbindelser
CY1106969T1 (el) Αναστολεις dpp-iv
WO2002089800A3 (en) N-aroyl cyclic amine derivatives as orexin receptor antagonists
EA200970171A1 (ru) Производные n-(аминогетероарил)-1н-индол-2-карбоксамидов, их получение и их применение в терапии
TWI256953B (en) Pyrimidine compounds
ATE507229T1 (de) Cucurbiturilderivate, die in wasser und organischen lösungsmitteln löslich sind, verfahren zu deren herstellung, verfahren zu deren trennung und deren anwendung
AR045909A1 (es) Formulacion solida que contiene un derivado de xantina
DE60142934D1 (de) Pharmazeutische dopamin-glykokonjugat-zusammensetzungen und verfahren zu deren herstellung
TW200738667A (en) Preparation method for dioxan-2-ylalkylcarbamate derivatives and intermediate thereof
SE0303541D0 (sv) New compounds
NO20063062L (no) Imidazolderivater, fremgangsmate for fremstilling og anvendelse av disse
DK1517890T3 (da) Kationisk substituerede diphenylazetidinoner, fremgangsmåde til deres fremstilling, lægemidler indeholdende disse forbindelser og deres anvendelse
MXPA05007848A (es) Derivados de arilalquilcarbamatos, su preparacion y su aplicacion en terapeutica.
WO2006017054A3 (en) Tricyclic-heteroaryl compounds useful as kinase inhibitors